vs
AFFILIATED MANAGERS GROUP, INC.（AMG）与UNITED THERAPEUTICS Corp（UTHR）财务数据对比。点击上方公司名可切换其他公司
UNITED THERAPEUTICS Corp的季度营收约是AFFILIATED MANAGERS GROUP, INC.的1.4倍（$790.2M vs $556.6M），AFFILIATED MANAGERS GROUP, INC.净利率更高（62.4% vs 46.1%，领先16.3%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs 6.2%），AFFILIATED MANAGERS GROUP, INC.自由现金流更多（$254.5M vs $173.3M），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs 5.5%）
Affiliated Managers Group（简称AMG）是一家成立于1993年的美国金融服务企业，总部位于佛罗里达州西棕榈滩。公司股票在纽约证券交易所挂牌交易，代码为AMG，同时是标普400美国中型企业指数的成份股。
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
AMG vs UTHR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $556.6M | $790.2M |
| 净利润 | $347.5M | $364.3M |
| 毛利率 | — | 86.9% |
| 营业利润率 | 94.4% | 45.1% |
| 净利率 | 62.4% | 46.1% |
| 营收同比 | 6.2% | 7.4% |
| 净利润同比 | 114.2% | 20.9% |
| 每股收益（稀释后） | $10.87 | $7.66 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $556.6M | $790.2M | ||
| Q3 25 | $528.0M | $799.5M | ||
| Q2 25 | $493.2M | $798.6M | ||
| Q1 25 | $496.6M | $794.4M | ||
| Q4 24 | $524.3M | $735.9M | ||
| Q3 24 | $516.4M | $748.9M | ||
| Q2 24 | $500.3M | $714.9M | ||
| Q1 24 | $499.9M | $677.7M |
| Q4 25 | $347.5M | $364.3M | ||
| Q3 25 | $212.4M | $338.7M | ||
| Q2 25 | $84.3M | $309.5M | ||
| Q1 25 | $72.4M | $322.2M | ||
| Q4 24 | $162.2M | $301.3M | ||
| Q3 24 | $123.6M | $309.1M | ||
| Q2 24 | $76.0M | $278.1M | ||
| Q1 24 | $149.8M | $306.6M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 87.4% | ||
| Q2 25 | — | 89.0% | ||
| Q1 25 | — | 88.4% | ||
| Q4 24 | — | 89.7% | ||
| Q3 24 | — | 88.9% | ||
| Q2 24 | — | 89.1% | ||
| Q1 24 | — | 89.2% |
| Q4 25 | 94.4% | 45.1% | ||
| Q3 25 | 68.7% | 48.6% | ||
| Q2 25 | 34.8% | 45.6% | ||
| Q1 25 | 25.5% | 48.2% | ||
| Q4 24 | 52.2% | 48.6% | ||
| Q3 24 | 42.0% | 45.8% | ||
| Q2 24 | 35.6% | 44.7% | ||
| Q1 24 | 50.8% | 52.6% |
| Q4 25 | 62.4% | 46.1% | ||
| Q3 25 | 40.2% | 42.4% | ||
| Q2 25 | 17.1% | 38.8% | ||
| Q1 25 | 14.6% | 40.6% | ||
| Q4 24 | 30.9% | 40.9% | ||
| Q3 24 | 23.9% | 41.3% | ||
| Q2 24 | 15.2% | 38.9% | ||
| Q1 24 | 30.0% | 45.2% |
| Q4 25 | $10.87 | $7.66 | ||
| Q3 25 | $6.87 | $7.16 | ||
| Q2 25 | $2.80 | $6.41 | ||
| Q1 25 | $2.20 | $6.63 | ||
| Q4 24 | $4.95 | $6.23 | ||
| Q3 24 | $3.78 | $6.39 | ||
| Q2 24 | $2.26 | $5.85 | ||
| Q1 24 | $4.14 | $6.17 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $586.0M | $2.9B |
| 总债务越低越好 | $2.7B | — |
| 股东权益账面价值 | $3.2B | $7.1B |
| 总资产 | $9.2B | $7.9B |
| 负债/权益比越低杠杆越低 | 0.83× | — |
8季度趋势，按日历期对齐
| Q4 25 | $586.0M | $2.9B | ||
| Q3 25 | $476.1M | $2.8B | ||
| Q2 25 | $361.0M | $3.0B | ||
| Q1 25 | $816.5M | $3.3B | ||
| Q4 24 | $950.0M | $3.3B | ||
| Q3 24 | $1.0B | $3.3B | ||
| Q2 24 | $865.5M | $3.0B | ||
| Q1 24 | $793.4M | $2.7B |
| Q4 25 | $2.7B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.6B | — | ||
| Q4 24 | $2.6B | — | ||
| Q3 24 | $2.6B | — | ||
| Q2 24 | $2.5B | — | ||
| Q1 24 | $2.5B | — |
| Q4 25 | $3.2B | $7.1B | ||
| Q3 25 | $3.3B | $6.6B | ||
| Q2 25 | $3.2B | $7.2B | ||
| Q1 25 | $3.2B | $6.8B | ||
| Q4 24 | $3.3B | $6.4B | ||
| Q3 24 | $3.3B | $6.1B | ||
| Q2 24 | $3.3B | $5.7B | ||
| Q1 24 | $3.6B | $5.3B |
| Q4 25 | $9.2B | $7.9B | ||
| Q3 25 | $8.9B | $7.4B | ||
| Q2 25 | $8.8B | $7.9B | ||
| Q1 25 | $8.7B | $7.7B | ||
| Q4 24 | $8.8B | $7.4B | ||
| Q3 24 | $8.9B | $7.1B | ||
| Q2 24 | $8.8B | $6.7B | ||
| Q1 24 | $9.0B | $6.5B |
| Q4 25 | 0.83× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.81× | — | ||
| Q1 25 | 0.82× | — | ||
| Q4 24 | 0.78× | — | ||
| Q3 24 | 0.79× | — | ||
| Q2 24 | 0.76× | — | ||
| Q1 24 | 0.70× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $256.4M | $346.2M |
| 自由现金流经营现金流 - 资本支出 | $254.5M | $173.3M |
| 自由现金流率自由现金流/营收 | 45.7% | 21.9% |
| 资本支出强度资本支出/营收 | 0.3% | 21.9% |
| 现金转化率经营现金流/净利润 | 0.74× | 0.95× |
| 过去12个月自由现金流最近4个季度 | $967.1M | $1.0B |
8季度趋势，按日历期对齐
| Q4 25 | $256.4M | $346.2M | ||
| Q3 25 | $277.1M | $562.1M | ||
| Q2 25 | $230.8M | $191.7M | ||
| Q1 25 | $208.9M | $461.2M | ||
| Q4 24 | $212.5M | $341.2M | ||
| Q3 24 | $265.2M | $377.2M | ||
| Q2 24 | $245.2M | $232.2M | ||
| Q1 24 | $209.2M | $376.5M |
| Q4 25 | $254.5M | $173.3M | ||
| Q3 25 | $275.9M | $351.6M | ||
| Q2 25 | $229.4M | $129.5M | ||
| Q1 25 | $207.3M | $386.3M | ||
| Q4 24 | $211.4M | $254.5M | ||
| Q3 24 | $264.5M | $300.7M | ||
| Q2 24 | $244.6M | $187.1M | ||
| Q1 24 | $208.2M | $338.3M |
| Q4 25 | 45.7% | 21.9% | ||
| Q3 25 | 52.3% | 44.0% | ||
| Q2 25 | 46.5% | 16.2% | ||
| Q1 25 | 41.7% | 48.6% | ||
| Q4 24 | 40.3% | 34.6% | ||
| Q3 24 | 51.2% | 40.2% | ||
| Q2 24 | 48.9% | 26.2% | ||
| Q1 24 | 41.6% | 49.9% |
| Q4 25 | 0.3% | 21.9% | ||
| Q3 25 | 0.2% | 26.3% | ||
| Q2 25 | 0.3% | 7.8% | ||
| Q1 25 | 0.3% | 9.4% | ||
| Q4 24 | 0.2% | 11.8% | ||
| Q3 24 | 0.1% | 10.2% | ||
| Q2 24 | 0.1% | 6.3% | ||
| Q1 24 | 0.2% | 5.6% |
| Q4 25 | 0.74× | 0.95× | ||
| Q3 25 | 1.30× | 1.66× | ||
| Q2 25 | 2.74× | 0.62× | ||
| Q1 25 | 2.89× | 1.43× | ||
| Q4 24 | 1.31× | 1.13× | ||
| Q3 24 | 2.15× | 1.22× | ||
| Q2 24 | 3.23× | 0.83× | ||
| Q1 24 | 1.40× | 1.23× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMG
暂无分部数据
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
